A Hydroquinone-Free Serum Claims to Hit Six Steps of Pigmentation. Here's What That Means at the Ingredient Level

A study published in Clinical, Cosmetic and Investigational Dermatology describes a cosmetic serum designed to interrupt pigmentation at six distinct points in what the researchers call the melanin life cycle: melanocyte activation, melanosome development, melanin production, melanosome transfer, melanosome degradation, and melanin removal. The authors, led by Kadoya and colleagues, call the serum the first to address all six steps. That claim comes from the paper itself, not from an independent body that verified it.

Most topical treatments for melasma and hyperpigmentation work on two of those six steps. A 2024 CCID review by Philipp-Dormston frames first-line topical therapy as targeting melanin production or melanosome transfer. Hydroquinone works this way, blocking tyrosinase, the enzyme that drives melanin production. The new serum adds four more targets. The one drawing the most attention is melanosome degradation, a mechanism that skin-lightening formulas rarely build in on purpose.

The formula is called the LTN Complex: lotus sprout extract, tranexamic acid, niacinamide. A separate paper from the testing lab Mattek identifies the active compounds in the lotus sprout extract as neferine and liensinine. That paper proposes that these compounds trigger a form of selective autophagy, the cell's internal recycling process, that targets melanosomes for breakdown. This looks like the source of the sixth pathway claim. Tyrosinase inhibition has decades of published mechanism behind it. Autophagy-driven melanosome clearance in a cosmetic formula does not.

The LTN Complex traces to a specific product: SkinMedica's Even & Correct Advanced Brightening Treatment, launched by Allergan Aesthetics in January 2023. Retail listings for that product cite a 9% LTN Complex. Other entries describing the same complex name cite concentrations of 2% and 6%. Lotus sprout extract and lotus seed extract appear interchangeably across sources describing what reads as the same ingredient. These are the kinds of details a formulation claim needs to hold together, and here they don't line up across the available sources, which likely reflects multiple SKUs sold under one complex name rather than one fixed formula.

The CCID paper is labeled exploratory. That is a weaker evidentiary tier than a randomized, blinded trial. A separate study in JAAD International, a randomized double-blind split-face trial with 113 participants (44 in a melasma subgroup), compared the same serum against 4% hydroquinone over 12 weeks. It reported comparable efficacy between the two, a mean hyperpigmentation reduction of 11.7% at week 12, and participant preference for the serum above 89%. An open-label study in the Journal of Drugs in Dermatology tested the serum in melasma and post-inflammatory hyperpigmentation patients with Fitzpatrick skin types IV through VI over 16 weeks. The mechanistic six-pathway claim sits in the weakest of these three papers. The efficacy claims against hydroquinone sit in the strongest.

The hydroquinone comparison is the product's reason for existing, not just a benchmark. The FDA proposed banning over-the-counter hydroquinone in 2006 over an animal carcinogenicity signal, a proposal the American Academy of Dermatology opposed on access grounds for patients with darker skin. Under the 2020 CARES Act, unapproved OTC hydroquinone products were required to leave the market by September 23, 2020. In April 2022, the FDA sent warning letters to 12 companies selling noncompliant OTC skin-lightening products containing hydroquinone. The only FDA-approved hydroquinone product left is Tri-Luma, available by prescription only. Any OTC pigment-correcting serum sold today is built against that regulatory gap, and the LTN Complex is one entry in a field of similar formulas racing to fill it.

Ortho Dermatologics has a competing serum called EV-I, targeting five melanin-synthesis pathways, with a reported 42% improvement on the Melasma Area and Severity Index at 12 weeks in an open-label study presented at the 2025 Science of Skin Summit. L'Oreal has its own multimodal serum study, authored by L'Oreal employees, published in the Journal of Drugs in Dermatology in January 2026. La Roche-Posay has backed an abstract comparing a 2-MNG and Melasyl serum against a tyrosinase-inhibitor product for post-inflammatory hyperpigmentation. Beiersdorf's Eucerin line markets thiamidol, described in the Philipp-Dormston review as the most effective human-tyrosinase inhibitor identified in vitro so far. Each of these papers comes from authors employed by or funded by the brand whose product they're testing.

Melasma relapses. The Philipp-Dormston review is explicit that it's a chronic, recurring condition, not one a single serum, ingredient, or active resolves permanently. A formula that clears pigment at six points in its life cycle still has to contend with a cycle that starts over.

The product listing for SkinMedica's Even & Correct serum gives the LTN Complex concentration as 9%. The CCID paper that tested the same complex at the center of its six-pathway claim does not state a percentage at all.